How Gene Editing Is Becoming Truly Personalized Medicine

In February 2025, a baby in Philadelphia became the first person in history to receive a gene editing therapy designed for nobody else on earth but him. KJ Muldoon was born with a rare metabolic disease so severe that roughly half of infants who have it do not survive their first year. Doctors at Children's Hospital of Philadelphia and Penn Medicine did not reach for an existing drug, because none existed. They built him one, from scratch, in about six months.

That story sounds like science fiction, and in 2020 it basically was. In 2026 it is turning into a repeatable process, backed by a brand new federal framework built specifically to make bespoke genetic medicine faster to develop and easier to approve. Here is how gene editing went from treating diseases to treating individual patients, and what still has to go right before that becomes normal rather than a headline.

A baby named KJ and the therapy built just for him

KJ Muldoon had severe carbamoyl phosphate synthetase 1 deficiency, an ultra-rare urea cycle disorder that leaves the body unable to clear ammonia from the blood, with an incidence of roughly one in 1.3 million births. He carried two different disease-causing mutations, one from each parent, and was too young for a liver transplant, the usual treatment of last resort. Researchers led by Kiran Musunuru and Rebecca Ahrens-Nicklas designed a base editing therapy, delivered through lipid nanoparticles straight to his liver cells, engineered to correct his exact mutation and nothing else.

The timeline is what makes the case remarkable. Manufacturing partners including the Innovative Genomics Institute and Danaher subsidiaries Aldevron and Integrated DNA Technologies built the custom guide RNA, base editor and safety testing package in roughly six months, and the FDA cleared the single patient application within about a week given the urgency of the case, as detailed in the New England Journal of Medicine case report and in Children's Hospital of Philadelphia's own account of the treatment. KJ received his first infusion in late February 2025, followed by two additional doses. By early 2026, at a Rare Disease Day event at the National Institutes of Health, his care team gave an update, he is walking, tolerating far more dietary protein than before, and living with a much milder version of a disease that once carried a coin flip's odds of killing him, though his [base editing] therapy did not cure the underlying condition outright.

Gene editing has a longer bespoke medicine history than you think

KJ's case grabbed headlines, but the idea of building a drug for exactly one patient did not start with CRISPR. In 2018, researchers designed milasen, a splice modulating antisense oligonucleotide, for a young girl named Mila Makovec who had a fatal, ultra-rare form of Batten disease. It became the first individualized genetic medicine ever given regulatory clearance, developed and dosed within about a year of her diagnosis, a template described in the original New England Journal of Medicine report on her treatment.

That single case opened a door that has not closed since. Antisense oligonucleotide therapies now exist for individual patients with conditions including ataxia telangiectasia and a rare inherited form of ALS, and researchers tracking the field estimate more than 30 people are currently being treated with custom antisense oligonucleotide therapy, with over 35 such drugs developed for more than 80 patients in total since milasen. What used to be a one time medical miracle is starting to look like an actual field, complete with its own manufacturing playbooks and, increasingly, n of 1 clinical trials designed specifically for a patient population of one.

Regulators are finally building a lane for this

The single biggest bottleneck for bespoke medicine has never really been the science, it has been proving a new drug works when there is only ever going to be one patient to study. On February 23 2026, the FDA published draft guidance on what it calls the Plausible Mechanism Framework, aimed squarely at that problem. According to the FDA's own guidance document, the framework lets sponsors support approval using strong mechanistic evidence and natural history data instead of a traditional randomized trial when patient populations are simply too small for one, and it explicitly names genome editing and RNA based therapies like antisense oligonucleotides as products that fit.

The framework goes further than just lowering the evidence bar for single patients. It allows variant specific versions of the same gene editing tool to be evaluated together under one master protocol, so a gene editing platform built to correct any of several related mutations in the same gene could, in principle, win approval based on results from as few as five to ten patients spread across multiple related disorders rather than requiring a separate trial for every mutation. That is a direct response to the approach Musunuru and Ahrens-Nicklas's team proposed after KJ's case, a reusable base and prime editing platform aimed at seven urea cycle disorders plus phenylketonuria, built around a single manufacturing and safety testing process that just swaps out the patient specific guide sequence. The FDA backed that shift up in April 2026 with additional draft guidance on evaluating off-target editing risk using modern sequencing technology, giving sponsors a clearer safety bar to design toward.

Why building a platform beats building one drug at a time

The logic behind all this regulatory movement is straightforward once you see it laid out. Building a completely new drug program for every single ultra-rare mutation, each with its own manufacturing process, toxicology package and regulatory filing, is far too slow and expensive to ever reach most of the roughly 7,000 known rare diseases, the large majority of which currently have no approved treatment at all. A platform approach flips that math. Once a base editor, delivery system and safety testing protocol have been validated once, treating the next patient mostly means swapping in a new guide sequence rather than starting from zero, which is exactly the efficiency rare disease drug development has been missing for decades.

That is also why the milasen precedent matters as much as KJ's case does. Both demonstrated, years apart, that a functioning template can be reused. Groups running N-of-1 antisense programs today are explicitly building on Mila's protocol rather than reinventing one for every new patient, and the FDA's new framework is essentially an attempt to do the same thing for gene editing at regulatory scale.

The catch nobody is glossing over

None of this makes personalized gene editing cheap, fast or broadly accessible yet, and it is worth being honest about that. Rare disease drugs already routinely cost hundreds of thousands to millions of dollars per patient even when they are not custom built, and a therapy engineered for exactly one person carries its own manufacturing overhead no matter how reusable the underlying platform becomes. KJ and Mila both had something else in common too, elite academic medical centers, philanthropic foundations and industry partners willing to move at extraordinary speed on their behalf. Most of the roughly 30 million Americans living with a rare disease, and the families still spending years just trying to get a diagnosis, do not have that kind of institutional backing lined up.

There is also a real scientific question the framework has not resolved, which is how confidently regulators and clinicians can extrapolate safety and efficacy from a handful of patients to the next mutation down the line. The FDA's own guidance leans heavily on natural history data, essentially knowing what typically happens to untreated patients, to make that judgment call, and that data simply does not exist yet for plenty of the rarest conditions on the list.

So is 2026 the year bespoke medicine actually arrives

The honest answer is that 2026 is the year the infrastructure for bespoke medicine arrived, even if the therapies themselves are still reaching a small number of patients. A regulatory pathway now exists that treats a gene editing platform more like a reusable drug delivery technology than a one-off experiment, and that shift alone could shorten the years-long odyssey rare disease families have historically faced from diagnosis to any treatment at all.

Whether that promise reaches beyond a handful of well-resourced hospitals and foundations is the real test still ahead. KJ Muldoon is walking today because a team of researchers, manufacturers and regulators moved faster than anyone thought possible. The next milestone worth watching is not another single dramatic case, it is whether that same speed becomes available to the family with no headline, no foundation and no six month sprint of favors, because that is where personalized medicine actually has to prove itself.